Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT01664182
Title Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications
Therapies
Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
City of Hope Comprehensive Cancer Center Duarte California 91010 United States Details
USC / Norris Comprehensive Cancer Center Los Angeles California 90033 United States Details
University of California Davis Comprehensive Cancer Center Sacramento California 95817 United States Details
City of Hope South Pasadena South Pasadena California 91030 United States Details
Wayne State University/Karmanos Cancer Institute Detroit Michigan 48201 United States Details
Mayo Clinic in Rochester Rochester Minnesota 55905 United States Details
Metro Minnesota Community Oncology Research Consortium Saint Louis Park Minnesota 55416 United States Details
Rutgers Cancer Institute of New Jersey New Brunswick New Jersey 08903 United States Details
UNC Lineberger Comprehensive Cancer Center Chapel Hill North Carolina 27599 United States Details
Penn State Milton S Hershey Medical Center Hershey Pennsylvania 17033-0850 United States Details
University of Pittsburgh Cancer Institute (UPCI) Pittsburgh Pennsylvania 15232 United States Details
VCU Massey Cancer Center at Hanover Medical Park Mechanicsville Virginia 23116 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field